- Home
- CTVA vs ARGX Comparison
CTVA vs ARGX Comparison
Compare CTVA & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTVA
- ARGX
- Stock Information
- Founded
- CTVA 2018
- ARGX 2008
- Country
- CTVA United States
- ARGX Netherlands
- Employees
- CTVA N/A
- ARGX N/A
- Industry
- CTVA Farming/Seeds/Milling
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTVA Consumer Staples
- ARGX Health Care
- Exchange
- CTVA Nasdaq
- ARGX Nasdaq
- Market Cap
- CTVA 39.2B
- ARGX 37.3B
- IPO Year
- CTVA N/A
- ARGX 2017
- Fundamental
- Price
- CTVA $63.13
- ARGX $647.39
- Analyst Decision
- CTVA Buy
- ARGX Strong Buy
- Analyst Count
- CTVA 18
- ARGX 20
- Target Price
- CTVA $65.50
- ARGX $653.11
- AVG Volume (30 Days)
- CTVA 3.1M
- ARGX 250.8K
- Earning Date
- CTVA 02-05-2025
- ARGX 02-27-2025
- Dividend Yield
- CTVA 1.08%
- ARGX N/A
- EPS Growth
- CTVA N/A
- ARGX N/A
- EPS
- CTVA 0.98
- ARGX N/A
- Revenue
- CTVA $16,637,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- CTVA $0.59
- ARGX $70.98
- Revenue Next Year
- CTVA $2.22
- ARGX $51.22
- P/E Ratio
- CTVA $64.26
- ARGX N/A
- Revenue Growth
- CTVA N/A
- ARGX 85.56
- 52 Week Low
- CTVA $44.91
- ARGX $349.86
- 52 Week High
- CTVA $64.20
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- CTVA 72.15
- ARGX 56.11
- Support Level
- CTVA $55.68
- ARGX $639.78
- Resistance Level
- CTVA $61.90
- ARGX $678.21
- Average True Range (ATR)
- CTVA 1.21
- ARGX 15.44
- MACD
- CTVA 0.75
- ARGX -0.45
- Stochastic Oscillator
- CTVA 99.60
- ARGX 52.74
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.